Purchase this article with an account.
V. Djafari, G. Davuluri, B. M. Glaser; Treatment of Choroidal Neovascularization Secondary to Choroidal Rupture With Intravitreal Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1438.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the results of two patients with choroidal neovascularization secondary to choroidal rupture treated with intravitreal bevacizumab.
Two patients with choroidal neovascularization secondary to choroidal rupture were treated with a single intravitreal dose of bevacizumab. The patients were followed clinically and with fluorescein angiography, high speed indocyanine green angiography, optical coherence tomography, and microperimetry.
After a single intravitreal dose of bevacizumab both patients showed markedly decreased leakage from the choroidal neovascular membrane and resolution of subretinal and intraretinal fluid. Central Retinal Thickness (CRT) decreased from 386 microns to 193 microns in Case 1 and from 310 microns to 177 microns in Case 2. Visual acuity improved from 20/80 to 20/25 in Case 1 and from 20/100 to 20/32 in Case 2. Both patients showed decreased size and density of macular scotoma with microperimetry testing. Neither patient needed further intervention as of the 3 month follow up.
Intravitreal bevacizumab may be an effective treatment for choroidal neovascularization secondary to choroidal rupture and a useful alternative to current treatment options.
This PDF is available to Subscribers Only